Last: | $18.41 |
---|---|
Change Percent: | -2.25% |
Open: | $18.66 |
Close: | $18.41 |
High: | $18.73 |
Low: | $18.1 |
Volume: | 57,768 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$18.41 | $18.66 | $18.41 | $18.73 | $18.1 | 57,768 | 04-24-2024 |
$18.25 | $17.64 | $18.25 | $18.46 | $17.64 | 121,611 | 04-23-2024 |
$16.94 | $16.78 | $16.94 | $17.02 | $16.69 | 148,847 | 04-22-2024 |
$16.5 | $16.31 | $16.5 | $16.53 | $16.21 | 61,049 | 04-19-2024 |
$16.36 | $16.34 | $16.36 | $16.53 | $16.07 | 187,961 | 04-18-2024 |
$16.45 | $16.78 | $16.45 | $17.13 | $16.22 | 295,240 | 04-17-2024 |
$16.68 | $16.98 | $16.68 | $16.98 | $16.45 | 107,426 | 04-16-2024 |
$17.66 | $17.74 | $17.66 | $17.82 | $17.44 | 62,840 | 04-15-2024 |
$17.88 | $17.88 | $17.88 | $18.1 | $17.68 | 92,838 | 04-12-2024 |
$18.09 | $18 | $18.09 | $18.14 | $17.9201 | 126,870 | 04-11-2024 |
$17.63 | $17.56 | $17.63 | $17.71 | $17.3101 | 83,494 | 04-10-2024 |
$17.94 | $18 | $17.94 | $18.05 | $17.33 | 359,981 | 04-09-2024 |
$16.87 | $16.65 | $16.87 | $17.22 | $16.65 | 78,348 | 04-08-2024 |
$16.36 | $16.67 | $16.36 | $16.67 | $16.19 | 51,431 | 04-05-2024 |
$16.87 | $17.08 | $16.87 | $17.32 | $16.77 | 85,601 | 04-04-2024 |
$16.93 | $17 | $16.93 | $17.12 | $16.83 | 188,592 | 04-03-2024 |
$16.72 | $16.73 | $16.72 | $16.98 | $16.4 | 128,944 | 04-02-2024 |
$16.77 | $16.82 | $16.77 | $16.82 | $16.63 | 38,074 | 04-01-2024 |
$16.8 | $16.93 | $16.8 | $17.05 | $16.69 | 62,060 | 03-29-2024 |
$16.8 | $16.93 | $16.8 | $17.05 | $16.69 | 62,060 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; ...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the ...
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor — ...